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Abstract
Background: The purpose of this study was to evaluate the effect of açai fruit pulp on risk factors for metabolic
disorders in overweight subjects. The açaí palm (Euterpe oleracea Mart.), which is native to South America, produces
a small, black-purple fruit which is edible. The fruit has recently become popular as a functional food due to its
antioxidant potential. Although several studies have been conducted in vitro and with animals, little is known
about the potential health benefits in humans aside from an increase in plasma anti-oxidant capacity. Metabolic
syndrome is a condition which is defined by a cluster of risk factors for cardiovascular disease and/or type-2
diabetes. Preliminary studies indicate that a reduction in reactive oxygen species can assist in the normalization of
the metabolic pathways involved in this syndrome.
Methods: This was an open label pilot study conducted with 10 overweight adults (BMI ≥ 25 kg/m
2 and ≤ 30 kg/
m
2) who took 100 g açai pulp twice daily for 1 month. The study endpoints included levels of fasting plasma
glucose, insulin, cholesterol, triglycerides, exhaled (breath) nitric oxide metabolites (eNO) and plasma levels of high
sensitivity C-reactive protein (hs-CRP). The response of blood glucose, blood pressure and eNO to a standardized
meal was determined at baseline and following the 30 day treatment.
Results: Compared to baseline, there were reductions in fasting glucose and insulin levels following the 30 day
treatment (both p < 0.02). There was also a reduction in total cholesterol (p = 0.03), as well as borderline
significant reductions in LDL-cholesterol and the ratio of total cholesterol to HDL-cholesterol (both p = 0.051).
Compared to baseline, treatment with açai ameliorated the post-prandial increase in plasma glucose following the
standardized meal, measured as the area under the curve (p = 0.047). There was no effect on blood pressure, hs-
CRP or eNO.
Conclusion: In this uncontrolled pilot study, consumption of açai fruit pulp reduced levels of selected markers of
metabolic disease risk in overweight adults, indicating that further studies are warranted.
Background
People who are overweight, particularly those with
excess central adipose tissue, are at risk of developing
dysfunctions in lipid and glucose metabolism resulting
in a propensity for cardiovascular disease and/or type-2
diabetes. This cluster of symptoms, which includes ele-
vated blood pressure, elevated fasting blood glucose
levels, elevated triglycerides and reduced levels of high-
density lipoprotein cholesterol, has been defined as
metabolic syndrome[1].
Oxidative stress, which is an imbalance between the
generation of free radical species and the activity of
anti-oxidant defense mechanisms, is thought to be one
of the underlying mechanisms behind the risk of cardio-
vascular disease and diabetes associated with obesity[2].
Subjects who are obese are more likely to have higher
levels of oxidative stress than those of normal weight. In
addition, weight loss is associated with a decrease in oxi-
dative stress[3]. Further, analysis of endogenous anti-
oxidant protection in subjects with metabolic syndrome
indicate that it is depressed[4]. And, subjects with
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oxidative damage, measured as elevated lipid peroxida-
tion and elevated protein carbonyls[3]. Oxidative stress
has also been shown to enhance insulin resistance and it
has been suggested that antioxidant therapy may reduce
insulin resistance in diabetic patients[4,5].
Diets which are high in fruits and vegetables, are
reported to increase plasma antioxidant capacity[6]. In
addition to vitamins C, E and beta-carotene, fruits and
vegetables contain phenolic compounds that contribute
to their antioxidant capacity[7]. The inverse relationship
between fruit and vegetable intake and the risk of cardi-
ovascular diseases and diabetes has been associated with
antioxidant capacity of these foods and in their phenolic
content[8,9]. Preclinical studies have reported that poly-
phenolics compounds have beneficial effects on glucose
absorption, insulin levels and lipid metabolism[10].
T h ef r u i to ft h ea ç a íp a l m( Euterpe oleracea Mart.),
which is native to South America has recently become
popular as a functional food due to its antioxidant
potential[11]. The edible fruit is round, black-purple in
color, about 1-inch (25 mm) in diameter and contains a
single large seed. Macerating the pulp of the fruit pro-
duces a viscous liquid which is approximately 2.4% pro-
tein and 5.9% lipid (by weight)[12]. Analysis of fatty acid
composition reveals that monounsaturated oleic acid is
the primary fat, present at 56.2%, followed by palmitic
(saturated fatty acid; 24.1%) and linoleic acid (polyunsa-
turated; 12.5%)[11]. Analysis of phenolics in the fruit
revealed the presence of anthocyanin 3-glycosides, feru-
lic acid, epicatechin, p-hydroxy benzoic acid, gallic acid,
protocatechuic acid, catechin, ellagic acid, vanillic acid,
p-coumaric acid and gallotannins[12]. Cyanidin-3-mono-
saccharides are reported to be present in the fresh pulp
at a concentration of 1040 ± 58 mg/L[13]. More specifi-
cally, the glucosides cyanidin-3-rutinoside and cyanidin-
3-glucose, were measured at concentrations of 1.93 and
1.17 mg/g dry weight, respectively, with a total antho-
cyanin content of 3.19 mg/g dry weight[11]. Açai pulp is
reported to have an antioxidant capacity of 48.6 μmol
Trolox equivalents (TE)/ml as measured using the oxy-
gen radical absorbance capacity (ORAC) assay[12].
Anthocyanins are generally considered to be the major
contributors to the antioxidant activity of the pulp.
However this concept has been challenged by a group of
researchers who estimated the contribution of the
anthocyanins to be just 10% of the total in vitro antioxi-
dant capacity and suggested that other, unidentified,
antioxidant constituents exist in the fruit[14]. This
group of researchers compared the Total Oxidant
Scavenging Capacity (TOSC) values for cyanidin-3-glu-
coside and cyanidin-3-rutoside to their corresponding
concentrations in açaí preparations and found that the
açaí preparations had significantly higher TOSC values
than the calculated capacity due to constituent cyanidin
glycosides.
In addition to the in vitro assays, the antioxidant
potential of preparations of açaí pulp and juice has also
been reported in animal and human studies. Experi-
ments with rats revealed that a diet supplemented with
2% açai pulp (dry wt/wt) for 6 weeks caused a reduction
in protein oxidation compared to control animals. Pro-
tein oxidation was measured as a decrease in carbonyl
protein and an increase in protein sulfhydryl groups.
There were also beneficial effects, compared to controls,
on antioxidant enzyme activity, measured as an increase
in serum paraoxonase, which is associated with preven-
tion/inhibition of lipoprotein oxidation. In animals fed a
hypercholesterolemic diet with or without açai pulp,
there was a decrease in serum superoxide dismutase
(SOD) activity compared to controls. SOD is an enzyme
which is induced in response to oxidative stress and
converts superoxide radicals into hydrogen peroxide[15].
In humans, plasma anti-oxidant capacity (measured
using the ORAC assay) in humans increased up to 3
fold with a single dose of 7 ml açaí pulp/kg body weight
compared to the control beverage (p < 0.01), with a t-
max of 3 hours[16]. The maximum plasma concentra-
tion (Cmax) of total anthocyanins, measured as cyanidin-
3-glucoside was reached 2.2 hours after consumption of
the pulp.This pharmacokinetic study included healthy
volunteers, who were dosed after a 72 hour dietary
washout phase and an overnight fast. The subjects con-
sumed a diet low in antioxidants that excluded the
majority of dietary polyphenolics. The antioxidant capa-
city was measured as the ratio of TE for each time point
compared to baseline, divided by the dose volume admi-
nistered to the subject.
As previously stated, reducing the production of reac-
tive oxygen species is hypothesized to assist in the nor-
malization of metabolic pathways that lead to the onset
of diabetes, endothelial dysfunction and cardiovascular
disease[2]. In a test of that hypothesis, this pilot study
was designed to evaluate the effects of a proprietary pre-
paration of açai pulp in overweight subjects who are at
risk for developing metabolic syndrome. Several studies
have been conducted on the effects on açai preparations
in vitro and in animals, but little is known about its
effects on humans. Epidemiological and experimental
studies point to the potential benefits of antioxidants in
ameliorating the risks of cardiovascular disease and dia-
betes type II, however the results from clinical studies
with antioxidant vitamins have been equivocal. The
study measured endpoints before and after administra-
tion of açai pulp for one month. Measurements included
levels of fasting plasma glucose, insulin, cholesterol and
triglycerides. Exhaled (breath) nitric oxide metabolites
(eNO) and plasma levels of high sensitivity C-reactive
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mation. The response of blood glucose, blood pressure
and eNO to a standardized meal was also determined.
Materials and methods
Investigational Product
The preparation used in this study was Sambazon
® Açai
Smoothie Pack (Sambazon Inc, San Clemente, CA), a
frozen product containing a puree of açai (Euterpe oler-
acea Mart.) pulp that is designed to be made into a
smoothie. The açai pulp was pasteurized and manufac-
tured in a GMP facility in Brazil. Initially a bulk pulp
containing 14% dry açai solids was produced and this
was diluted with water to produce the Smoothie Pack
which contained 11% solids (11 g). The bulk pulp con-
tained 6.42 g fatty acids per 100 g: 61.4% octadecenoic
acids (18:1; including oleic acid), 20.8% hexadecanoic
acids (16:0; palmitic) and 11.2% octadecadienoic acids
(18:2; linoleic acid). The bulk pulp also contained 3.5
mg/ml total phenolics measured as gallic acid equiva-
lents and 0.77 mg/ml total anthocyanins measured as
cyanidin-3-glucoside equivalents (as analyzed by Bruns-
wick Laboratories, MA). In vitro antioxidant capacity of
the hydrophilic contents, measured as micromole Trolox
equivalency using the ORAC assay, was 46 μmole TE/ml
[17]. This activity accounted for 98.9% of the ORAC
activity; only a little more than 1% of the in vitro antiox-
idant capacity was found in the lipid-soluble fraction.
Nutrition analysis of the 100 g Pack performed by Silli-
ker, Inc. Southern CA Laboratory (Cypress, CA)
revealed the 100 g Pack contained 71.8 calories, 5.8 g
total carbohydrate (<0.25 g sugars), 4.9 g total fat (1.1 g
saturated fat), 5.33 g fiber and 1.0 g protein.
The participants were instructed to place the contents
of the Sambazon
® Açai Pulp into a Blender Bottle
®,
adding water and up to 4 g (1 packet) of sugar as
desired making a “smoothie”. As a measurement of
compliance, the participants took a photo of each
smoothie and e-mailed the photo to the research coordi-
nators before drinking. The dose was 100 g twice daily,
taken in the morning and evening. A diary was kept
noting whether each smoothie was consumed and the
corresponding photo sent.
Subjects
Subjects were included if they were 18-65 years of age,
had a BMI ≥ 25 kg/m
2 and ≤ 30 kg/m
2 and agreed to
all study visits and procedures as well as not to initiate/
change any exercise or diet programs during the study.
Females of child-bearing age agreed to use approved
forms of birth control. Subjects were required to have a
cell phone with a camera along with the ability to trans-
mit photos and to agree to use their cell phone for
study purposes. Subjects were excluded if they had any
major systemic, inflammatory or chronic diseases, had
an infection, used diabetic medications in the 4 weeks
prior to the study, used insulin currently or in the past
3 years, had symptomatic hypoglycemia in the past
month, used immunosuppressive drugs in the prior 5
years, smoked cigarettes, or abused alcohol/drugs.
Females who were pregnant or lactating were also
excluded. Subjects with a baseline exhaled nitric oxide
(eNO) measurement of > 35 ppb were also excluded.
Intake of steroids, anti-inflammatory drugs, multi-vita-
mins and anti-oxidants were prohibited during the
study.
Study Design
This was an open label pilot study conducted with 10
overweight adult men and women who took Sambazon
®
Açai pulp 100 g twice daily for 1 month. As this was a
pilot study and there was no prior human data on the
effects of the Açai product from which to perform a
power calculation, the sample size was set at 10. The
study was conducted at the Staywell Research clinical
research site located in Northridge, CA. and was moni-
tored by the Medicus Research Contract Research Orga-
nization. Institutional Review Board approval was
obtained from the Copernicus Group IRB (Cary, NC)
prior to the initiation of any study related procedures.
Good Clinical Practices (GCP) were followed throughout
the study and all subjects gave informed consent accord-
ing to GCP guidelines.
The clinical study began in October 2009 (first subject
in) and lasted until December 2009 (last subject com-
pleted). The subjects in the study came to the research
clinic for a total of 4 visits (V1-V4). The maximum
treatment duration was 4 weeks. There was a window of
± 2 days for V2, V3 and V4. The subjects were given a
handout listing foods containing nitrates (for example
bacon and hot dogs) and asked to avoid these foods for
the duration of the study.
V1 was a screening visit during which the subjects
were screened for inclusion and exclusion criteria, gave
informed consent and medical history, received a physi-
cal examination, had a review of current medications,
demographic assessment, urine collection (pregnancy
test for females of child bearing age) and were dispensed
standardized frozen foods which were the only foods to
be consumed during the 24 hours prior to the next visit.
V2 was the baseline visit for which the subjects arrived
fasting (since mid-night the night before), having
avoided exercise and alcohol for 24 hours and caffeine
s i n c e8p mt h en i g h tb e f o r e .T h e yh a dap h y s i c a le x a m
during which vital signs were noted along with anthro-
pometric measures (body weight, height and circumfer-
ences of waist/hip). Baseline determinations were made
of blood glucose (capillary), insulin, cholesterol (total
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glycerides), exhaled (breath) nitric oxide metabolites
(eNO) and high sensitivity C-reactive protein (hs-CRP).
Blood glucose was measured using finger prick samples
(Bayer Ascensia Contour Glucometer). Insulin was mon-
itored using a chemilumiscent method on a DPC Immu-
lyte Analyzer. Lipid levels and hs-CRP were determined
using an Olympus AU 2700 Autoanalyzer. eNO was
measured using a devise developed by Insight eNO Sys-
tem (previously Apieron Inc, Menlo Park, CA, now
Aerocrine AB, Sweden). The devise measures eNO via
an optical biosensor that undergoes a change in its opti-
cal absorbance when binding with nitric oxide[18].
Following the visit’s baseline determinations, the sub-
jects consumed a standardized meal (57 g carbohydrate,
50 g fat, 18 g protein, nitrate-free; Stouffer’s Fettuccini
Alfredo, Nestlé USA, Wilkes-Barre, PA). eNO was deter-
mined 1 hour and 2 hours after the meal. Blood pres-
sure and blood glucose (capillary) levels were
determined 30, 60, 90 and 120 minutes after the meal.
After all tests were complete, the study products were
dispensed as well as diaries (Daily dosing diary and 3-
day food recall diary). V3 was scheduled 2 weeks follow-
ing visit 2. During this visit, compliance was assessed by
collecting product packaging dispensed at the previous
visit. The diaries administered at the last visit were col-
lected and new diaries were dispensed. Also dispensed
were standardized frozen foods to be consumed during
the 24 hours prior to next visit (V4). During V4 the
measurements conducted during V2 were repeated.
Compliance was again assessed and diaries administered
at the last visit were collected.
Statistical Analysis
Excel 2003 (Microsoft Corp, Redmond WA) was used
for data entry, validation, restructuring, calculating
changes in variables over time, reorganizing and refor-
matting results, and preparing the graph. Statistical ana-
lyses (descriptive statistics and Student t tests) were
performed using SPSS Base System ver. 17 (IBM SPSS
Inc., Chicago IL.).
The percent changes in capillary blood glucose levels
from time zero to 120 minutes after the meal were
determined for each individual. The averages of the
individual percent changes were calculated and plotted
as minutes from time zero (baseline). The area under
the curve (AUC) was calculated using the Trapezoidal
Rule.
Results
The demographics of the ten participants in the study is
given in Table 1. Their body measurements did not
change significantly over the month of the study. Three-
day food recall diaries were collected at baseline and
after 4 weeks of treatment. Based on the assessment of
macronutrient content (fat, protein, carbohydrates) and
total caloric intake, the diet of the subjects did not
change over the course of the study. The subjects took
100 g açai pulp twice daily for one month. Compliance,
as measured using photographs of the prepared
smoothies, was 100%.
The subjects mean baseline fasting glucose level was
98.0 ± 10.1 mg/dl, which is on the upper edge of normal
(70 to 99 mg/dl) (Table 2)[1]. After one month adminis-
tration of the açai pulp, the mean fasting glucose level
decreased significantly to 92.8 ± 10.9 mg/dl (p = 0.018).
The mean plasma fasting insulin levels for the group
d e c r e a s e df r o m8 . 9±5 4μU/ml at baseline, to 6.7 ± 33
μU/ml (p = 0.017). (Table 2)
Consumption of açai reduced total cholesterol from
159 ± 37 mg/dl to 142 ± 28 mg/dl (p = 0.03).
Table 1 Participant Demographics
Number 10
Age (years) 18-46 (mean 28.1)
Sex 5 men, 5 women
Race 9 Hispanic, 1 Caucasian
Marital status 5 single, 4 married, 1 divorced
Body weight (lbs) 173.0 ± 18.1*
BMI 27.4 ± 1.8*
Waist/hip ratio 0.86 ± 0.06*
* mean ± standard deviation
Table 2 Measurements before and after administration of
açai pulp
Measurement Time Mean Std. Deviation Sig.
Fasting Glucose (mg/dl) Baseline 98.0 10.1 .018
Day 30 92.8 10.9
Insulin (μU/ml) Baseline 8.92 5.4 .017
Day 30 6.68 3.3
Serum Cholesterol (mg/dl) Baseline 159.2 37.4 .030
Day 30 141.8 28.3
Cholesterol Ratio Baseline 3.79 1.0 .051
Day 30 3.42 0.9
VLDL (mg/dl) Baseline 26.2 13.5 .111
Day 30 20.9 8.3
LDL (mg/dl) Baseline 90.1 29.1 .051
Day 30 78.1 25.3
HDL (mg/dl) Baseline 42.9 8.4 .953
Day 30 42.8 9.3
Triglycerides (mg/dl) Baseline 130.8 67.3 .116
Day 30 104.2 41.6
Measurements of glucose, insulin and lipid levels before and after
administration of Sambazon açai for 30 days (given as means and standard
deviations) were compared using paired t-tests to determine the significance
of the change from baseline.
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sity lipoprotein (LDL)-cholesterol from slightly elevated
to within the optimal range (p = 0.51). Levels of high
density lipoprotein (HDL)-cholesterol did not change
significantly following intake of açai. The ratio of total
cholesterol to HDL-cholesterol, obtained by dividing the
HDL cholesterol level into the total cholesterol, was
r e d u c e df r o m3 . 7 9±1 . 0a tb a s e l i n et o3 . 4 2±0 . 9a f t e r
treatment (p = 0.051). There was no significant change
over time in levels of very low density lipoprotein
(VLDL) cholesterol or triglycerides (Table 2).
The mean baseline measurement for highly sensitive
C-reactive protein (hs-CRP) was 2.7 ± 3.0 mg/L and did
not change significantly following administration of açai.
The effects of consumption of a standardized meal (57
g carbohydrate, 50 g fat, 18 g protein, nitrate-free) on
plasma glucose, mean exhaled nitric oxide (eNO) and
blood pressure were determined before (baseline) and
after 30 days of consumption of açai pulp. The averages
of individual percent changes in capillary blood glucose
levels from time zero to 120 minutes after the meal are
plotted in Figure 1. At the baseline visit, the postpran-
dial glucose levels peaked at 60 minutes, with an
increase of 14.7%. After 30 days of consumption of açaí,
the percent change from baseline at 60 minutes was
o n l y4 . 7 % .T h eg l u c o s ea r e au n d e rt h ec u r v e( A U C )
measurement for the baseline visit was 205.6 ± 18.6 and
after 30 days of açaí was 189.7 ± 26.3 (mean ± standard
deviation). The difference was significant (p = 0.047).
Thus, consumption of açai pulp for 30 days significantly
reduced the post-prandial increases in glucose levels fol-
lowing the standardized meal. There were no significant
changes in blood pressure or in eNO. Mean baseline
blood pressures were 119 ± 7 mmHg systolic and 72 ±
9 mmHg diastolic at baseline. The mean exhaled nitric
oxide (eNO) level at baseline was 17.5 ± 7.6 ppb, within
the normal range of less than 25 ppb.
Açai pulp was safely consumed. There were no
adverse events or changes in vital signs (body tempera-
ture, pulse or respiratory rate).
Discussion
According to the American Heart Association[19], a
BMI of 25 kg/m
2 corresponds to about 10 percent over
ideal body weight. People with BMIs in this range are
considered to have an increased risk of developing dys-
functions in glucose/insulin levels and lipid metabolism.
The subjects in this study had a mean BMI of 27.4 and
were categorized as overweight (BMI 25 to 29.9). Con-
sumption of Sambazon
® Açai by this population,
reduced plasma levels of fasting glucose, insulin and
total cholesterol. Consumption of Sambazon
® Açai also
reduced the post-prandial increase in plasma glucose
following a meal.
Epidemiologic studies on the prevention of diabetes
have shown that overweight subjects randomized to var-
ious lifestyle interventions who demonstrated reductions
in fasting glucose of 4 mg/dL (3.6%) and in cholesterol
o f5m g / d L( 2 . 3 % )h a das i g n i f i c a n tr e d u c t i o n( 5 8 % )i n
the risk of becoming diabetic[20]. In this study, the
reductions in fasting glucose and total cholesterol com-
p a r e dt ob a s e l i n ew e r e5 . 3 %a n d1 0 . 6 % .T h e s er e d u c -
tions are greater than those deemed necessary for a
change in risk status.
The potential effects of other anthocyanin-rich pre-
parations on glucose levels in subjects with ether dia-
betes type 2 or metabolic syndrome have been tested
clinically. Choke berry (Aronia melanocarpa) juice (200
mls) given to subjects with type 2 diabetes (200 ml/day
for 3 months) reduced fasting glucose levels (13.3 ± 4.5
to 9.1 ± 3.0 mmol/l) and hemoglobin (Hb)A1c levels
(9.3 ± 2.2 to 7.5 ± 1.3) compared to baseline (both p <
0.001)[21]. However, another study in which an extract
of choke berry (3 × 100 mg/day) was given to 25 sub-
jects with metabolic syndrome for 2 months, did not
show any effect on fasting plasma glucose levels (base-
line 92.9 ± 11.0 mg/dl)[22]. A preparation of concen-
trated sour cherry (Prunus cerasus) juice (40 g/day for 6
weeks) given to 17 women with diabetes type 2 resulted
in significantly reduced HbA1c levels compared to base-
line (7.9 ± 1.6 to 7.5 ± 1.2; p < 0.05) but no significant
reduction in fasting glucose levels (baseline 158.3 ± 43.4
mg/dl)[23].
The possible effects of anthocyanins on diabetes as
well as possible mechanisms of action have been
















Figure 1 Post-prandial levels of plasma glucose were
measured before and up to 120 minutes after consumption of
a standardized meal. The determination of the percent change in
glucose from baseline was made at the start of the study (baseline
curve) and after administration of Sambuzon açai for 30 days (30-
day curve). The trend lines for the baseline and 30 day
measurements are depicted as two straight lines.
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(a type 2 diabetic model) for 5 weeks ameliorated hyper-
glycemia and increased insulin sensitivity compared to
control animals. In this study, stimulation of AMP-acti-
vated protein kinase was measured in white adipose tis-
sue, skeletal muscle and the liver. This effect was
accompanied by an upregulation of glucose transporter
4 in adipose tissue and muscle, and a suppression of
glucose production and lipid content in the liver[24]. A
black soybean seed coat preparation, delivering a dose
of 50 mg anthocyanins/kg by gavage for 30 days, was
reported to increase expression of glucose transporter 4
proteins in skeletal muscle and heart tissue in streptozo-
tocin-induced diabetic rats[25]. Purified cyanidin 3-glu-
coside (2 g/kg diet for 5 weeks) ameliorated
hyperglycemia and increased insulin sensitivity in dia-
betic mice. The authors reported that cyanidin 3-gluco-
side upregulated glucose transporter 4 and down
regulated retinol binding protein 4 expression[26].
In the present study, total and LDL cholesterol were
reduced as well as the ratio of total cholesterol to HDL-
cholesterol. A reduction in total and LDL-cholesterol
coupled with an increase in HDL-cholesterol is consid-
ered to be a step towards prevention of cardiovascular
disease. The results of this study are in line with those
reported in a rat study in which açai pulp reduced total
and non-HDL cholesterol in treated animals compared
to controls. In this study, the animals were fed a
hypercholesterolemic diet with and without 2% açaí (dry
wt/wt) for 6 weeks[15]. An extract of choke berry (3 ×
100 mg/day) given to 25 subjects with metabolic syn-
drome for 2 months significantly decreased levels of
total cholesterol, LDL and triglycerides compared to
baseline, while HDL levels did not change[22]. However,
the previously mentioned preparation of concentrated
sour cherry juice (40 g/day for 6 weeks) given to women
with diabetes type 2 did not significantly alter lipid
levels[23].
Treatment with açai did not affect blood pressure in
this study. An effect on blood pressure was suggested by
an in vitro study conducted using an extract of açai fruit
(injections of 10 to 100 mg extract) added to rat mesen-
teric vascular bed previously contracted with norepi-
nephrine. The study demonstrated that açai had an
endothelium-dependent vasodilator effect due to effects
on production of nitric oxide[27].
C-reactive protein (CRP) is one of the acute phase
proteins that increases during systemic inflammation
and measuring CRP levels in the blood is useful as an
indicator of cardiovascular disease risk. An effect of
anthocyanins on CRP in has not been established in pre-
vious clinical studies. This was also the case in a
recently reported 2 month study in which an extract of
choke berry (3 × 100 mg/day) was given to 25 subjects
with metabolic syndrome for 2 months[22]. In accor-
dance with previous results, this study did not demon-
strate any significant change in levels of hs-CRP
following administration of açai.
Exhaled nitric oxide (eNO) is an indicator of airway
inflammation. There was no indication of airway inflam-
mation in subjects in this study at baseline and no
increase in eNO following the standardized meal. There
i sar e p o r to fa ni n c r e a s ei ne N Of o l l o w i n gah i g hf a t
meal (74 g fat; 1 g fat/kg body weight) in healthy sub-
jects[28]. However that finding was not repeated in this
study.
Açai pulp was safely consumed in this study at a dose
of 100 g twice daily for one month. Experiments with
mice found that doses of 3.3 to 16.7 g açaí pulp per kg
b o d yw e i g h t ,g i v e ni . p .o n c eo rd a i l yf o r1 4c o n s e c u t i v e
days, did not cause any genotoxic effects[29].
This was an open label, uncontrolled, pilot study
designed to explore the potential effects of Sambazon
®
Açai on risk factors for diabetes and cardiovascular dis-
ease. The limitations of this study are a lack of a blind-
ing, a placebo control and the small sample population.
This was an exploratory study, and as the results are
positive, further studies placebo-controlled studies with
a larger study population are warranted.
Conclusions
In this uncontrolled pilot study, consuming 200 g per
day of Sambazon
® Açai for 1 month reduced fasting
levels of plasma glucose, insulin, and total cholesterol
compared to baseline levels in a cohort of 10 overweight
adults. Administration of Açai for 30 days also attenu-
ated the post-prandial glucose response (AUC) following
a standardized meal compared to the pre-treatment
response. Sambazon
® Açai was administered safely,
without adverse events. The results of this study suggest
that conducting a larger placebo-controlled trial to
determine the effects of acai on risk factors for chronic
disease is warranted.
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